Proteomics

Dataset Information

Advanced Assesement Through Intact Glycopeptide Analysis of Infliximab Biologics and Biosimilar


ABSTRACT: We demonstrated high-resolution tandem mass spectrometry with an ultra-high-performance liquid chromatography for characterization and comparison between biologics and biosimilar of infliximab at an advanced level. Comparing the N- and O-glycopeptides profiles, a total of 49 and 54 glycopeptides was identified for each product of the biologics and biosimilar, respectively. We also discovered one novel N-glycosylation site at the light chain from both biopharmaceuticals and one novel O-glycopeptide at the heavy chain from only biosimilar. Site-specific glycopeptide analysis process will be a robust and useful technique for evaluating therapeutic mAbs and complex glycoprotein products.

INSTRUMENT(S): Orbitrap Fusion Eclipse

ORGANISM(S): Infliximab

SUBMITTER: Heeyoun Hwang  

PROVIDER: MSV000090073 | MassIVE | Wed Aug 03 05:35:00 BST 2022

SECONDARY ACCESSION(S): PXD035788

REPOSITORIES: MassIVE